The fastest, most cost-effective solution for conducting online surveys in APAC
TOKYO, April 28 (Bernama-GLOBE NEWSWIRE) -- GMO Research, Inc. (https://gmo-research.com/), a leading online research solution platform provider in the APAC region, has rolled out a new initiative to support companies in conducting online research projects with the fastest and most cost-effective turnaround in APAC.
There is an increasing demand for DIY market research tools that allow companies to conduct survey research remotely and at low costs. But when a company really starts to plan a research project, there are some common obstacles. Firstly, the targeted audience is limited to the company’s own service and/or product line, so the company cannot collect a larger number of responses. Secondly, recruiting people for a survey is a time-consuming and costly process. And lastly, localizing questionnaires, ensuring they align with local law, and checking that the contents address the cultural and linguistic background correctly takes a great deal of effort.
To address these issues, GMO Research has developed “MO Lite”, a new service that enables companies to link their own using DIY market research tools to recruit survey respondents directly from one of the largest pool of panelists in APAC, with a price less as USD 10 cent per question, that comes with full support from APAC local experts.
* USD 300 minimum fee will be included.
Takashi Ito, Chief Global Officer of GMO Research, Inc., comments: “With the rising demand for quick and cost-efficient choices for conducting surveys, it just came naturally to us that we would connect the largest consumer panel network in APAC with the most commonly used free survey tool, to bring great value to the market. We are confident that MO Lite can serve as one of the most viable options for conducting surveys in APAC. It is obviously the fastest, most cost-effective, and most reliable solution.”
For questions & inquiries: https://gmo-research.com/services/diy-survey-sampling
MO Lite inquiries:
MO Lite Project Team
Email: info@gmo-research.jp
Advantages of using MO Lite:
(1) Surveys can be conducted on people other than your own target audience
(2) Surveys can be sent out as soon as one business day after application.
(3) You can distribute to more than 200 pre-targeted attributes* at no additional cost.
* Targeted attributes are the attributes of monitors that have been databased through a large-scale screening survey conducted in advance by the Asia Cloud Panel.
About GMO Research:
GMO Research offers an all-in-one online research solution platform that allows direct access to one of the largest consumer panel networks in APAC: Asia Cloud Panel. Asia Cloud Panel currently consists of over 40 million online panelists, ranging from consumers to CEOs, across 15 APAC markets. GMO Research is part of and backed by GMO Internet Group, one of the largest internet conglomerates in Japan, specializing in a number of internet-related technologies. GMO Internet Group has the number one Japanese market share in internet security, payment processing, e-commerce solutions, web hosting, domain, and FX trading.
To find out more about GMO Research, visit https://gmo-research.com.
GMO Internet Group
GMO Internet Group is an Internet service industry leader, developing and operating Japan’s most widely used domain, hosting & cloud, ecommerce, security, and payment solutions. The Group also includes the world’s largest online FX trading platform, as well as online advertising, Internet media, and cryptoassets related services. GMO Internet, Inc. (TSE: 9449) is headquartered in Tokyo, Japan. For more information, please visit https://www.gmo.jp/en/.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8aab8aba-6299-4d0f-b36e-16f836d0a5a0
SOURCE : GMO Internet, Inc.
Wednesday 28 April 2021
GMO RESEARCH TO LAUNCH NEW SERVICE BRAND "MO LITE"
JOBDIVA MAKES HIRING MORE EFFICIENT BY INTEGRATING WITH JOBS ON FACEBOOK
NEW YORK, April 28 (Bernama-GLOBE NEWSWIRE) -- JobDiva is proud to announce an integration with Jobs on Facebook—one of the first integrations of its kind.
Jobs on Facebook makes it simple for employers and recruiters to post jobs, manage applications and communicate with candidates more easily. By synchronizing job openings, JobDiva’s integration with Jobs on Facebook empowers businesses to reach candidates where they are spending significant amounts of time.
“At JobDiva, we are focused on reducing unemployment during these uncertain times, as well as matching the workforce with their desired opportunities by maximizing our clients’ capabilities—and doing so quickly, in the interest of the public at large,” said Gus Samra, JobDiva’s Chief Revenue Officer. “JobDiva’s integration with Jobs on Facebook is a signal example of our commitment to talent and client success, and we’re ecstatic to offer this integration.”
About JobDiva: JobDiva, the leading global ATS, is delivered to clients via the cloud. JobDiva stands as the top-tier ATS, defining the path of innovation in staffing technology.
Contact:
Bella Chen
Head of Marketing, JobDiva
Bella.chen@jobdiva.com
+1 212-384-6566
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65890c74-c25d-4a3c-a1a1-b11802201711
SOURCE : JobDiva
ANALYTICA ANNOUNCES EXPANSION OF ENHANCED INFUSION SYSTEM INTO MIDDLE EAST
Analytica signs agreement with Marwa for distribution, marketing and sales of the Enhanced Infusion System (EIS) in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.- Patented IV add-in infusion system reduces infection and embolism risk and saves medical staff time for an overall lower total cost than existing equipment and practices.
BRISBANE, Australia, April 28 (Bernama-GLOBE NEWSWIRE) -- Analytica Limited (ASX:ALT), the Australian developer of the Enhanced Infusion System (EIS) and PeriCoach® pelvic floor exercise system for the treatment of stress urinary incontinence, has entered into an agreement with Marwa’s Office for Export & Import Medical Supplies (Marwa) to distribute, market and sell the EIS to hospital systems in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.
The EIS technology was developed by Analytica under the project names AutoStart and AutoFlush and has been sold in Australia with the trade name FirstFlow™,¹ under limited license. EIS combines the AutoStart and AutoFlush patented technologies into a simple and inexpensive solution.
The patented float system automatically restarts IV fluid flow following medication delivery, thereby saving healthcare workers’ time, reducing hospital costs and preventing the adverse events associated with air embolism and failure of Peripheral Intravenous Catheters (PIVC). The EIS reacts immediately, silently and without intervention or programming. It can be retrofitted to any existing infusion system design and can work in harmony with and improve the capability of any infusion pump or ‘bag’ infusion system, regardless of sophistication.
Use of the EIS uniquely allows a completely closed infusion system, with integrity achieved by reducing the interactions believed to cause mechanical and vascular complications as well as good flushing and/or patency practice.
The EIS has an Australian TGA ARTG registration and USFDA 510(k) clearance. It is fully compliant with ISO 8536 infusion system and other relevant standards.
The EIS can markedly reduce legal risks by addressing multiple factors that can impact patients, clinicians and hospitals, including:
- Air Embolism – The EIS has a large and heavy float valve ensuring complete, long-term seal. The unique float maintains a seal even at extreme angles (up to 60 degrees from horizontal), making the device usable in ambulances, retrieval and military situations and reducing the risk of mortality and morbidity associated with air embolism.
- Open/Closed Delivery System – The needle-free access port is the only entry point, with only one syringe necessary per medication event. Using the existing 1L IV bag means replacement is less frequent than 100mL pre-mix bags, saving time and money and reducing the risk of contamination and infection.
- Syringe Flush – This feature eliminates the requirement to introduce an additional flushing syringe and bolus. Flushing prevents interactions between incompatible fluids/medications, thus reducing the risk of cross contamination and strengthening infection control.
- Catheter Flush – This feature reduces the risk of PIVC failure with the automatic, immediate restart of IV flow after medication delivery, which allows continuous maintenance flow to the flush line and catheter. This also maintains catheter patency by preventing internal luminal occlusion.
- Medication Dilution – The Interrupted Therapy feature allows the introduction of medication through EIS to accurately measure IV fluid mix rather than 3-way valve and bags.
- Infection Risk – Observational studies demonstrate high incidence of non-conformance to hand washing and flushing protocol. EIS limits access and infection opportunity.
- Flushing pressure – Bolus flush of catheter may vary based on syringe size and pressure. The proprietary float design ensures constant flushing pressure, reducing the risk of PIVC failure.
Given the health and legal risk-reduction features of the EIS, the home-based hospital care market represents a growth opportunity globally. The EIS is compact, rugged and does not require a pump or energy source, which makes it suitable for retrieval, military and third world needs without compromising risk.
To view a video about the operation and features of the EIS, please click here.
Marwa’s Principal has extensive experience with the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.
“Marwa has presented a compelling opportunity with experienced professionals to take Analytica’s Enhanced Infusion System (EIS) into a large and growing market in the Middle East,” said Dr. Michael Monsour, Chairman of Analytica Ltd. “We look forward to working with Marwa to expand the usage of our unique EIS technology.”
For more information about Analytica and the Enhanced Infusion System, visit www.AnalyticaMedical.com
For investor or business inquiries, please contact: investorrelations@analyticamedical.com
For media inquiries, please contact: Annie Starr, astarr@6degreespr.com
About Analytica Limited
Analytica is a product development and commercialisation company based in Brisbane, Australia that is focussed on Class I and II medical device products.
Analytica is the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to decrease nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.
Analytica is also the manufacturer of the PeriCoach® System, an e-health treatment system for women who suffer stress urinary incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles because of pregnancy, childbirth and menopause.
____________________
¹ Trademark of ICU Medical Australia.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7af8a18-4b05-4cae-a8bb-71d578ab84fc
SOURCE : Analytica Limited
To view a video about the operation and features of the EIS, please click here.
Marwa’s Principal has extensive experience with the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.
“Marwa has presented a compelling opportunity with experienced professionals to take Analytica’s Enhanced Infusion System (EIS) into a large and growing market in the Middle East,” said Dr. Michael Monsour, Chairman of Analytica Ltd. “We look forward to working with Marwa to expand the usage of our unique EIS technology.”
For more information about Analytica and the Enhanced Infusion System, visit www.AnalyticaMedical.com
For investor or business inquiries, please contact: investorrelations@analyticamedical.com
For media inquiries, please contact: Annie Starr, astarr@6degreespr.com
About Analytica Limited
Analytica is a product development and commercialisation company based in Brisbane, Australia that is focussed on Class I and II medical device products.
Analytica is the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to decrease nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.
Analytica is also the manufacturer of the PeriCoach® System, an e-health treatment system for women who suffer stress urinary incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles because of pregnancy, childbirth and menopause.
____________________
¹ Trademark of ICU Medical Australia.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d7af8a18-4b05-4cae-a8bb-71d578ab84fc
SOURCE : Analytica Limited
Monday 26 April 2021
MONDE NISSIN'S IPO RECEIVES PSE APPROVAL
Not for Publication or Distribution in the United States, European Economic Area, the United Kingdom, Canada, Japan, and Australia
MAKATI CITY, Philippines, April 26 (Bernama-BUSINESS WIRE) -- Monde Nissin Corporation (“Monde Nissin” or the “Company”) today announced it has received the Notice of Approval from the Philippine Stock Exchange (“PSE”) for its proposed initial public offering of its Common Shares (the “Offer”). The PSE approval comes one day after the Company received pre-effective approval from the Philippine Securities and Exchange Commission (“SEC”).
As previously announced, Monde Nissin plans to issue up to approximately 20% of the issued and outstanding capital stock of the Company after completion of the Offer if the overallotment option is not exercised. The Company intends to use the net proceeds from the primary offer to fund Capital Expenditure, redemption of the Arran Convertible Note, and repayment of loans to commercial banks.
MNC’s timetable of the Offer is expected to be as follows:
MAKATI CITY, Philippines, April 26 (Bernama-BUSINESS WIRE) -- Monde Nissin Corporation (“Monde Nissin” or the “Company”) today announced it has received the Notice of Approval from the Philippine Stock Exchange (“PSE”) for its proposed initial public offering of its Common Shares (the “Offer”). The PSE approval comes one day after the Company received pre-effective approval from the Philippine Securities and Exchange Commission (“SEC”).
As previously announced, Monde Nissin plans to issue up to approximately 20% of the issued and outstanding capital stock of the Company after completion of the Offer if the overallotment option is not exercised. The Company intends to use the net proceeds from the primary offer to fund Capital Expenditure, redemption of the Arran Convertible Note, and repayment of loans to commercial banks.
MNC’s timetable of the Offer is expected to be as follows:
- Pricing Date: May 18, 2021
- Offer Period: May 24, 2021 to May 28, 2021
- Listing Date and Commencement of Trading in the PSE: June 7, 2021
The final timing of the Offer, final offer price, final number of offer shares, and allocation of the proceeds will depend on market conditions, the circumstances surrounding the Offer, and will be subject to favorably securing the remaining necessary regulatory approvals.
Commenting on the approvals, the Company stated: “We are grateful for the PSE and SEC’s favorable consideration of our registration statement, subject to compliance with certain conditions. We are excited about the prospect of becoming a global public company and believe that Monde Nissin provides a compelling investment opportunity. We combine the stability of our Asia-Pacific Food and Beverage business and the strong positions that our noodles, crackers and baked goods have in the Philippines with the exciting growth opportunities from Quorn, which is poised to build on its loyal customers and expand its reach and product offerings to compete and win in the rapidly growing global meat alternatives market.”
UBS AG Singapore Branch, Citigroup Global Markets Limited and J.P. Morgan Securities plc will serve as Joint Global Coordinators and Joint Bookrunners for the proposed offering. BDO Capital & Investment Corporation, BPI Capital Corporation and First Metro Investment Corporation will be the Local Lead Underwriters and Joint Bookrunners. Credit Suisse (Singapore) Limited will serve as the Joint International Bookrunner. Macquarie Capital Securities (Singapore) Pte. Limited and Jefferies Singapore Limited will serve as the International Co-Bookrunners. China Bank Capital Corporation, PNB Capital and Investment Corporation and SB Capital Investment Corp. will be the Domestic Co-Lead Underwriters.
A copy of the draft preliminary offering circular on the Offer is available on Monde Nissin’s website at www.mondenissin.com.
A registration statement relating to these securities has been filed with the Philippines Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This communication is not for distribution, directly or indirectly, in or into the United States (including is territories and possessions, any State of the United States and the District of Columbia). This communication is not an offer and does not form a part of any offer of securities for sale in the United States or elsewhere. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933 (the Securities Act), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No money, securities or other consideration is being solicited by this communication or the information contained herein and, if sent in response to this communication or the information contained herein, will not be accepted.
About Monde Nissin
Monde Nissin Corporation is a global food and beverages company headquartered in the Philippines, with a portfolio of iconic and market leading brands across fast-growing categories, including Lucky Me! noodles, SkyFlakes crackers, Fita crackers, Monde baked goods and Quorn meat alternative products. The Company aspires to improve the well-being of people and the planet, and create sustainable solutions for food security. That aspiration is reflected in our commitment to continuously improve our products to make them more delicious, nutritious, and better for the planet. For more information, please visit www.mondenissin.com.
About Quorn
Quorn Foods is a global market leader in healthy, sustainable protein. Headquartered in Stokesley, North Yorkshire in the United Kingdom, the company offers a wide range of great-tasting products to appeal to the rapidly expanding group of people wanting to reduce their meat consumption. The company employs around 900 people and exports to 15 countries around the world, including Australia, Singapore and the United States. Quorn® is one of the United Kingdom’s top 40 FMCG brands. Quorn Foods Ltd is the reporting group which includes a main trading company, Marlow Foods Ltd. Quorn Foods Ltd encompasses all international operations of Quorn® and Cauldron®. For more information, please visit www.quorn.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20210423005332/en/
Contact
Philippines Media
Monde Nissin
Mark Tiangco
corp.comm@mondenissin.com
International Media
Sard Verbinnen & Co
Ron Low, Jay Qin and Eve Young
MondeNissin-SVC@sardverb.com
Source : Monde Nissin Corporation
Commenting on the approvals, the Company stated: “We are grateful for the PSE and SEC’s favorable consideration of our registration statement, subject to compliance with certain conditions. We are excited about the prospect of becoming a global public company and believe that Monde Nissin provides a compelling investment opportunity. We combine the stability of our Asia-Pacific Food and Beverage business and the strong positions that our noodles, crackers and baked goods have in the Philippines with the exciting growth opportunities from Quorn, which is poised to build on its loyal customers and expand its reach and product offerings to compete and win in the rapidly growing global meat alternatives market.”
UBS AG Singapore Branch, Citigroup Global Markets Limited and J.P. Morgan Securities plc will serve as Joint Global Coordinators and Joint Bookrunners for the proposed offering. BDO Capital & Investment Corporation, BPI Capital Corporation and First Metro Investment Corporation will be the Local Lead Underwriters and Joint Bookrunners. Credit Suisse (Singapore) Limited will serve as the Joint International Bookrunner. Macquarie Capital Securities (Singapore) Pte. Limited and Jefferies Singapore Limited will serve as the International Co-Bookrunners. China Bank Capital Corporation, PNB Capital and Investment Corporation and SB Capital Investment Corp. will be the Domestic Co-Lead Underwriters.
A copy of the draft preliminary offering circular on the Offer is available on Monde Nissin’s website at www.mondenissin.com.
A registration statement relating to these securities has been filed with the Philippines Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
This communication is not for distribution, directly or indirectly, in or into the United States (including is territories and possessions, any State of the United States and the District of Columbia). This communication is not an offer and does not form a part of any offer of securities for sale in the United States or elsewhere. The securities referenced herein have not been and will not be registered under the United States Securities Act of 1933 (the Securities Act), or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No money, securities or other consideration is being solicited by this communication or the information contained herein and, if sent in response to this communication or the information contained herein, will not be accepted.
About Monde Nissin
Monde Nissin Corporation is a global food and beverages company headquartered in the Philippines, with a portfolio of iconic and market leading brands across fast-growing categories, including Lucky Me! noodles, SkyFlakes crackers, Fita crackers, Monde baked goods and Quorn meat alternative products. The Company aspires to improve the well-being of people and the planet, and create sustainable solutions for food security. That aspiration is reflected in our commitment to continuously improve our products to make them more delicious, nutritious, and better for the planet. For more information, please visit www.mondenissin.com.
About Quorn
Quorn Foods is a global market leader in healthy, sustainable protein. Headquartered in Stokesley, North Yorkshire in the United Kingdom, the company offers a wide range of great-tasting products to appeal to the rapidly expanding group of people wanting to reduce their meat consumption. The company employs around 900 people and exports to 15 countries around the world, including Australia, Singapore and the United States. Quorn® is one of the United Kingdom’s top 40 FMCG brands. Quorn Foods Ltd is the reporting group which includes a main trading company, Marlow Foods Ltd. Quorn Foods Ltd encompasses all international operations of Quorn® and Cauldron®. For more information, please visit www.quorn.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20210423005332/en/
Contact
Philippines Media
Monde Nissin
Mark Tiangco
corp.comm@mondenissin.com
International Media
Sard Verbinnen & Co
Ron Low, Jay Qin and Eve Young
MondeNissin-SVC@sardverb.com
Source : Monde Nissin Corporation
ERGOMED EXPANDS OPERATIONS IN JAPAN
RNS
PRESS RELEASE
PRESS RELEASE
Ergomed expands operations in Japan
New legal entity and regional office established in Tokyo responding to client demand
Guildford, UK, April 26 (Bernama-GLOBE NEWSWIRE) -- Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that its PrimeVigilance business, a global leader in the provision of pharmacovigilance and medical information services, has established its new legal entity and regional office in Japan and is fully operational from 26 April 2021.
The new subsidiary company, trading as PrimeVigilance Japan KK, is based in Tokyo and offers a comprehensive range of pharmacovigilance services, including a dedicated Japanese safety database. Full Japanese language Medical Information services are also provided.
This expansion provides existing and prospective international PrimeVigilance clients the opportunity to extend their product coverage into the strategically important Japanese pharmaceutical market, the fourth largest globally after the US, the EU and China. It also provides PrimeVigilance and Ergomed the opportunity to provide high quality specialist services to domestic Japanese companies, opening up a new market.
PrimeVigilance has a strong operational presence in Europe and the recent acquisitions of Ashfield PV and MedSource, as well as significant organic growth in the US, have elevated PrimeVigilance into a market leading position in North America. The new facility in Japan adds Asia to Ergomed’s global footprint, enabling PrimeVigilance to offer operational services in all major regions, with pharmacovigilance and medical information professionals based in each territory, providing both local and global expertise.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “Ergomed has provided a breadth of services and expertise in Asia both as a CRO and as a pharmacovigilance specialist through its outsourcing model for many years. With a solid base of international clients in Japan, Ergomed is establishing its own pharmacovigilance and medical information infrastructure to serve current and future clients and further strengthen our global operational and commercial footprint in the strategically important Asia region. Following the two US acquisitions in 2020 of Ashfield Pharmacovigilance (now PrimeVigilance USA) and MedSource, this marks another major step in our strategy to establish Ergomed as a leading international pharmaceutical services specialist.”
ENDS
Enquiries:
Ergomed plc
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Tel: +44 (0) 1483 402 975
Numis Securities Limited
Freddie Barnfield / Matthew O’Dowd (Nominated Adviser)
James Black (Broker)
Tel: +44 (0) 20 7260 1000
Consilium Strategic Communications
Chris Gardner / Matthew Neal
Olivia Manser / Angela Gray
Tel: +44 (0) 20 3709 5700
ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.
SOURCE : Ergomed plc
Friday 23 April 2021
CONAGEN'S NOVEL SOLUTION TO MAKING NATURAL CAPSAICIN BY FERMENTATION ACCESSIBLE
Bedford, Mass., April 23 (Bernama-GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules.
Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors.
Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality.
The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, including food, cosmetic, personal care, pharmaceutical and medical. In industrial applications, such as anti-fouling paint for boats and ships, capsaicin has the potential to replace heavy metals.
“The successful scale-up of our fermentation process for capsaicinoids is a good example of Conagen’s innovative advancements in gene discovery, strain engineering and process development and optimization,” said Dr. Casey Lippmeier, vice president of innovation at Conagen. “The complimentary addition of capsaicinoids to our product portfolio enhances our motivation to meet consumers’ demand for sustainable, nature-based, and clean ingredients.”
Two major capsaicinoids, capsaicin and dihydrocapsaicin are responsible for roughly up to 90% of the pungency in chili pepper.
Yet, another capsaicinoid, nonivamide, also known as Pelargonic Acid Vanillylamide, (PAVA) is found in small, trace amounts in hot peppers. It is an alternative to capsaicin for its hot sensation and spicy flavoring. Nonivamide is typically used in topical muscle pain relievers and synthetic pepper spray, respectfully.
Due to the extremely low content of nonivamide in hot peppers, and the large demand, current plant extraction methods are not commercially viable. Thus, nonivamide has exclusively been made by chemical synthesis. Although chemically synthesized nonivamide is readily available, consumers are adopting clean and natural products.
Providing a solution to global capsaicin shortages, Conagen has identified several key genes in the capsaicin biosynthetic pathway in hot peppers and has demonstrated proof-of-concepts for the production of capsaicin, dihydrocapsaicin, and nonivamide. Several patents have been granted to Conagen for microbial production of capsaicinoids.
As a result of the demand for a natural, low cost-in-use solution, Conagen has successfully optimized and scaled-up its fermentation process for the production of capsaicin, dihydrocapsaicin, and nonivamide.
###
About Conagen
Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop sustainable, nature-based molecules bio-manufactured into the highest quality products available. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com
Attachment
Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors.
Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality.
The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, including food, cosmetic, personal care, pharmaceutical and medical. In industrial applications, such as anti-fouling paint for boats and ships, capsaicin has the potential to replace heavy metals.
“The successful scale-up of our fermentation process for capsaicinoids is a good example of Conagen’s innovative advancements in gene discovery, strain engineering and process development and optimization,” said Dr. Casey Lippmeier, vice president of innovation at Conagen. “The complimentary addition of capsaicinoids to our product portfolio enhances our motivation to meet consumers’ demand for sustainable, nature-based, and clean ingredients.”
Two major capsaicinoids, capsaicin and dihydrocapsaicin are responsible for roughly up to 90% of the pungency in chili pepper.
Yet, another capsaicinoid, nonivamide, also known as Pelargonic Acid Vanillylamide, (PAVA) is found in small, trace amounts in hot peppers. It is an alternative to capsaicin for its hot sensation and spicy flavoring. Nonivamide is typically used in topical muscle pain relievers and synthetic pepper spray, respectfully.
Due to the extremely low content of nonivamide in hot peppers, and the large demand, current plant extraction methods are not commercially viable. Thus, nonivamide has exclusively been made by chemical synthesis. Although chemically synthesized nonivamide is readily available, consumers are adopting clean and natural products.
Providing a solution to global capsaicin shortages, Conagen has identified several key genes in the capsaicin biosynthetic pathway in hot peppers and has demonstrated proof-of-concepts for the production of capsaicin, dihydrocapsaicin, and nonivamide. Several patents have been granted to Conagen for microbial production of capsaicinoids.
As a result of the demand for a natural, low cost-in-use solution, Conagen has successfully optimized and scaled-up its fermentation process for the production of capsaicin, dihydrocapsaicin, and nonivamide.
###
About Conagen
Conagen is making the impossible possible. Our scientists and engineers use the latest synthetic biology tools to develop sustainable, nature-based molecules bio-manufactured into the highest quality products available. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. For more information, visit www.conagen.com
Attachment
DYADIC INTERNATIONAL HOSTING A FIRESIDE CHAT ON "THE POTENTIAL OF THE TRANSFORMATIVE DYADIC C1 PROTEIN TECHNOLOGY IN HELPING MEET GLOBAL HEALTH CHALLENGES"
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
JUPITER, Fla., April 23 (Bernama-GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
The moderated discussion will include the following Key Opinion Leaders (KOLs):
JUPITER, Fla., April 23 (Bernama-GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on developing and deploying its proprietary C1-cell protein production platform to optimize the development of vaccines, therapeutics and other protein based products today announced that it will host a fireside chat on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
The moderated discussion will include the following Key Opinion Leaders (KOLs):
- Alain Townsend, Ph.D. – Weatherall Institute - Oxford University
- Albert Osterhaus, P.V.M, Ph.D. – Erasmus Medical Centre
- Cecil Nick – Parexel (Clinical & Regulatory Support)
- Joris Vandeputte – International Alliance for Biological Standardization
The discussion will include:
- Regulatory considerations and advantages of the C1 platform
- Case studies describing the successful production of high value antigens for both Schmallenburg Virus and Rift Valley Fever Virus in relation to the performance in other production platforms
- The efforts being undertaken by Dyadic to address the emerging SARS-CoV-2 variants including Dyadic’s development efforts advancing a SARS-CoV-2 receptor binding domain (RBD) vaccine candidate – DYAI-100 plus the rapid engineering of C1 cell lines to express known and emerging variants
- The C1 platform’s potential for developing and manufacturing multi-valent COVID-19 and other subunit vaccines, including a pan-coronavirus vaccine that can protect against most or all variants
- Glycoengineering C1-cells to produce mAbs and other antibodies
The conversation will be moderated by Dr. David Bramhill, a veteran in the biotechnology industry with extensive experience using a wide array of protein production technologies including E. coli, Saccharomyces cerevisiae, Pichia pastoris, Tetrahymena, Insect SF9 stable cells (not baculovirus), CHO, and HEK293.
You are invited to join this important discussion. You will learn why Dyadic and a growing number of key opinion leaders and subject matter experts believe that Dyadic’s C1 protein production platform presents a robust production solution for the cost effective flexible scale commercial production of therapeutics and vaccines.
You can register for the fireside chat here.
Alain Townsend, Ph.D. is an Immunologist at the Weatherall Institute of Molecular Medicine, University of Oxford, who has been working on COVID-19 over the last year.
Most of Dr. Townsend's work has been concerned with the presentation of Influenza antigens with class I molecules of the Major Histocompatibility complex. In the past, he identified the major targets for T cells as the conserved nucleoprotein and matrix protein components of the virus and demonstrated that a system of cytosolic antigen presentation exists that passes peptides derived from these proteins into the ER where they bind to class I MHC molecules. With the recent pandemic, this interest continues with a practical extension into the issue of whether heterotypic immunity (between pandemic strains) can be induced in man with live attenuated strains of influenza. We have developed our own design of live attenuated virus called S-FLU, that relies on mutations in the haemagglutinin signal sequence that are permissive for infection but prevent replication of the virus. The advantage of this approach is that all of the viral proteins are expressed in their appropriate context in the lung, and thus can induce a full set of local T and B cell responses. Dr. Townsend is developing methods to deliver the vaccine virus by aerosol in collaboration with Ronan Mac Loughlin at Aerogen. Preliminary results in collaboration with Dr. Kanta Subbarao (NIH) show that our vaccine viruses are capable of preventing illness caused by the most virulent forms of influenza in a murine and ferret infection model, and we are studying responses in the pig as a relevant large animal (in collaboration with Elma Tchillian, Pirbright). Dr. Townsend is presently investigating the mechanisms of this immunity in the pig.
Albert Osterhaus, P.V.M, Ph.D. has been Head of the Department of Viroscience at Erasmus MC Rotterdam until 2014, is currently Director of the Center of Infection Medicine and Zoonosis Research and Guest-Professor at the University of Veterinary Medicine Hannover. He has a long track record as a scientific researcher and Principal Investigator of numerous major scientific projects. At Erasmus MC, Professor Osterhaus has run a diagnostic virology lab with more than 40 staff and a research virology lab with over 150 personnel. His research programme follows a novel integrated “viroscience” concept, bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies on human and animal virus infections. Among the major accomplishments are the discovery of more than 70 new viruses of humans and animals (e.g. human metapneumovirus, coronaviruses, influenza viruses), elucidation of the pathogenesis of major human and animal virus infections, and development of novel intervention strategies.
The international recognition of Professor Osterhaus is further highlighted by major prizes, guest lecture invitations, (co-)organiserships of international meetings and editorships of scientific journals. Professor Osterhaus has acted as mentor for more than 80 PhD students and holds several key patents. He is also the author of more than 1300 papers in peer-reviewed journals, together cited more than 70,000 times, and his H index is > 116. Currently he also is Chair of the European Working Group on Influenza (ESWI). He organised numerous international scientific conferences on influenza and other emerging infections, holds several senior editorships and received numerous prestigious awards. He is member of the Dutch and German National Academies of Sciences, member of the Belgium Academia of Medicine, and Commander of the Order of the Dutch Lion.
Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and clinical development for over 30 years; for over 25 years he has focused on biological medicines. Mr. Nick has particular expertise in monoclonals and biosimilars, having worked on over 20 such programs, engaged in over 50 interactions and meetings with regulatory agencies in the EU, US, Canada, Australia, Mexico, Brazil and supported 6 submissions in the EU and US. He has also participated extensively in Industry and International meetings on the subject. Additionally, Mr. Nick has extensive experience in orphan drugs and in numerous therapeutic areas including, but not limited to, oncology, inflammatory disease, diabetes, growth and hematology.
Mr. Nick is a Fellow of TOPRA and has been a guest lecture at Cardiff University MSc in Clinical Research and Greenwich University MSc in Pharmaceutical Sciences courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has authored many articles on regulatory and clinical development issues.
Dr. Joris Vandeputte, President of IABS (International Alliance for Biological Standardization), is a founding member of IABS-EU, the European affiliate of IABS. Since 1955, IABS is the global independent platform, where stakeholders meet for exchange on science and issues related to vaccines, cell and gene therapy and human Biotherapeutics. IABS stimulates consensus building that eventually results in regulatory frameworks and recommendations to decision makers. In December 2019, IABS and VAC2VAC organised the conference Animal testing for vaccines - Implementing Replacement, Reduction and Refinement: Challenges and Priorities Bangkok, Thailand, December 3-4, 2019
Dr. Vandeputte got his Doctor's degree in Veterinary Medicine in 1976 at Gent University, Faculty of Veterinary Medicine, Belgium. As a virologist at this University (1976-1980), Joris discovered H1N1 flu as a pathogen for swine, leading to a better understanding of H1N1 as a zoonosis. Subsequently, at the Belgian Ministry of Agriculture, he worked on animal disease control in Belgium and the European Union before joining Institut Mérieux, Rhône Mérieux, which became Merial. Dr. Vandeputtehas more than 35 years science, industry and international organisation’s experience. He has been involved in the complete value chain of vaccines: research, development, and production, regulatory and marketing.
About C1 Protein Production Platform
The C1 protein production platform presents a significant opportunity to leverage an industrial protein production technology to transcend the limits of legacy protein production technologies enabling large scale production of therapeutics and vaccines. In the new normal of global vaccination the world needs a versatile and reliable protein production technology that provides rapid response and robust, cost effective production. Since 2016, Dyadic has been busy re-engineering the C1 protein production platform to produce recombinant glycoprotein based vaccines & therapeutics for human and animal health applications.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com
SOURCE : Dyadic International, Inc.
You are invited to join this important discussion. You will learn why Dyadic and a growing number of key opinion leaders and subject matter experts believe that Dyadic’s C1 protein production platform presents a robust production solution for the cost effective flexible scale commercial production of therapeutics and vaccines.
You can register for the fireside chat here.
Alain Townsend, Ph.D. is an Immunologist at the Weatherall Institute of Molecular Medicine, University of Oxford, who has been working on COVID-19 over the last year.
Most of Dr. Townsend's work has been concerned with the presentation of Influenza antigens with class I molecules of the Major Histocompatibility complex. In the past, he identified the major targets for T cells as the conserved nucleoprotein and matrix protein components of the virus and demonstrated that a system of cytosolic antigen presentation exists that passes peptides derived from these proteins into the ER where they bind to class I MHC molecules. With the recent pandemic, this interest continues with a practical extension into the issue of whether heterotypic immunity (between pandemic strains) can be induced in man with live attenuated strains of influenza. We have developed our own design of live attenuated virus called S-FLU, that relies on mutations in the haemagglutinin signal sequence that are permissive for infection but prevent replication of the virus. The advantage of this approach is that all of the viral proteins are expressed in their appropriate context in the lung, and thus can induce a full set of local T and B cell responses. Dr. Townsend is developing methods to deliver the vaccine virus by aerosol in collaboration with Ronan Mac Loughlin at Aerogen. Preliminary results in collaboration with Dr. Kanta Subbarao (NIH) show that our vaccine viruses are capable of preventing illness caused by the most virulent forms of influenza in a murine and ferret infection model, and we are studying responses in the pig as a relevant large animal (in collaboration with Elma Tchillian, Pirbright). Dr. Townsend is presently investigating the mechanisms of this immunity in the pig.
Albert Osterhaus, P.V.M, Ph.D. has been Head of the Department of Viroscience at Erasmus MC Rotterdam until 2014, is currently Director of the Center of Infection Medicine and Zoonosis Research and Guest-Professor at the University of Veterinary Medicine Hannover. He has a long track record as a scientific researcher and Principal Investigator of numerous major scientific projects. At Erasmus MC, Professor Osterhaus has run a diagnostic virology lab with more than 40 staff and a research virology lab with over 150 personnel. His research programme follows a novel integrated “viroscience” concept, bringing together world-leading scientists in molecular virology, immunology, epidemiology, pathogenesis, and intervention studies on human and animal virus infections. Among the major accomplishments are the discovery of more than 70 new viruses of humans and animals (e.g. human metapneumovirus, coronaviruses, influenza viruses), elucidation of the pathogenesis of major human and animal virus infections, and development of novel intervention strategies.
The international recognition of Professor Osterhaus is further highlighted by major prizes, guest lecture invitations, (co-)organiserships of international meetings and editorships of scientific journals. Professor Osterhaus has acted as mentor for more than 80 PhD students and holds several key patents. He is also the author of more than 1300 papers in peer-reviewed journals, together cited more than 70,000 times, and his H index is > 116. Currently he also is Chair of the European Working Group on Influenza (ESWI). He organised numerous international scientific conferences on influenza and other emerging infections, holds several senior editorships and received numerous prestigious awards. He is member of the Dutch and German National Academies of Sciences, member of the Belgium Academia of Medicine, and Commander of the Order of the Dutch Lion.
Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and clinical development for over 30 years; for over 25 years he has focused on biological medicines. Mr. Nick has particular expertise in monoclonals and biosimilars, having worked on over 20 such programs, engaged in over 50 interactions and meetings with regulatory agencies in the EU, US, Canada, Australia, Mexico, Brazil and supported 6 submissions in the EU and US. He has also participated extensively in Industry and International meetings on the subject. Additionally, Mr. Nick has extensive experience in orphan drugs and in numerous therapeutic areas including, but not limited to, oncology, inflammatory disease, diabetes, growth and hematology.
Mr. Nick is a Fellow of TOPRA and has been a guest lecture at Cardiff University MSc in Clinical Research and Greenwich University MSc in Pharmaceutical Sciences courses and Biotech Module leader for the TOPRA MSc course. He was on the editorial panel of SCRIP Clinical Research and has authored many articles on regulatory and clinical development issues.
Dr. Joris Vandeputte, President of IABS (International Alliance for Biological Standardization), is a founding member of IABS-EU, the European affiliate of IABS. Since 1955, IABS is the global independent platform, where stakeholders meet for exchange on science and issues related to vaccines, cell and gene therapy and human Biotherapeutics. IABS stimulates consensus building that eventually results in regulatory frameworks and recommendations to decision makers. In December 2019, IABS and VAC2VAC organised the conference Animal testing for vaccines - Implementing Replacement, Reduction and Refinement: Challenges and Priorities Bangkok, Thailand, December 3-4, 2019
Dr. Vandeputte got his Doctor's degree in Veterinary Medicine in 1976 at Gent University, Faculty of Veterinary Medicine, Belgium. As a virologist at this University (1976-1980), Joris discovered H1N1 flu as a pathogen for swine, leading to a better understanding of H1N1 as a zoonosis. Subsequently, at the Belgian Ministry of Agriculture, he worked on animal disease control in Belgium and the European Union before joining Institut Mérieux, Rhône Mérieux, which became Merial. Dr. Vandeputtehas more than 35 years science, industry and international organisation’s experience. He has been involved in the complete value chain of vaccines: research, development, and production, regulatory and marketing.
About C1 Protein Production Platform
The C1 protein production platform presents a significant opportunity to leverage an industrial protein production technology to transcend the limits of legacy protein production technologies enabling large scale production of therapeutics and vaccines. In the new normal of global vaccination the world needs a versatile and reliable protein production technology that provides rapid response and robust, cost effective production. Since 2016, Dyadic has been busy re-engineering the C1 protein production platform to produce recombinant glycoprotein based vaccines & therapeutics for human and animal health applications.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: prawson@dyadic.com
SOURCE : Dyadic International, Inc.
Subscribe to:
Posts (Atom)